Laura L. Turunen
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.
Journal: bioRxiv : the preprint server for biology
Published: April 27, 2026
Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.
Journal: NPJ precision oncology
Published: July 23, 2025
Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.
Journal: NPJ precision oncology
Published: July 23, 2025
Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 07, 2024
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Journal: Antiviral research
Published: November 15, 2023
Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.
Journal: Cell reports methods
Published: December 16, 2022
Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT).
Journal: SLAS discovery : advancing life sciences R & D
Published: October 07, 2022
Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates.
Journal: SLAS discovery : advancing life sciences R & D
Published: August 31, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.
Journal: NPJ precision oncology
Published: May 05, 2022
iTReX: Interactive exploration of mono- and combination therapy dose response profiling data.
Journal: Pharmacological research
Published: September 10, 2021
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Journal: Cancer discovery
Published: June 08, 2021
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma.
Journal: Scientific reports
Published: April 08, 2021
Last Updated: 09/26/2026